Abstract 1537P
Background
Pevonedistat (MLN4924/TAK924), which is an inhibitor of NEDD8 (neural precursor cell expressed developmentally down-regulated protein 8)-activating enzyme (NAE), shows synergistic effects with platinum, suggesting possibility of conquest over platinum-resistance, in preclinical studies. This phase I study was conducted to determine the recommended dose (RD) of pevonedistat in combination with capecitabine plus oxaliplatin (CapeOX) and explore its efficacy and safety as third- or later line treatment in patients (pts) with unresectable advanced gastric cancer (AGC).
Methods
This study consisted of two parts: the dose-finding part, and the expansion part at the RD. In both parts, treatment was started as monotherapy with pevonedistat for a week (Lead-in) and followed by 3-drug combination in a 3-week cycle: Capecitabine (1000 mg/m2/day, twice daily, for 14 days), oxaliplatin (130 mg/m2 on day 1) and pevonedistat (20 mg/m2 in level 1, 15 mg/m2 in level 0, on days 1, 3, and 5). Pharmacokinetics (PK) of pevonedistat was compared between its mono and combination therapy. Translational research for pharmacodynamics and genetic biomarkers were performed.
Results
Between April 2019 and September 2021, 12 pts having prior chemotherapy containing fluoropyrimidine plus platinum were enrolled. The initial 2 pts in the level 1 experienced DLTs (grade 3 elevation in ALT and AST, delay of starting cycle 2). After confirming that six pts in the level 0 showed no DLTs, 4 pts were added in the expansion part. Grade3 AEs included AST increased (25%), ALT increased (17%), and platelet count decreased (17%). No obvious difference in the PK of pevonedistat was observed when combined with CapeOX. Two (17%) and 8 (75%) pts achieved partial response and disease control. The median overall and progression-free survival were 9.3 and 4.4 months. Inhibition of NAE by pevonedistat was confirmed in all patients by positive Cdt1 expression in the post-treatment biopsy. No genetic alterations associated with efficacy were identified.
Conclusions
Pevonedistat plus CapeOX was well tolerated and showed promising efficacy in AGC pts previously treated with platinum containing chemotherapy.
Clinical trial identification
jRCT2031190020.
Editorial acknowledgement
Legal entity responsible for the study
H. Shoji.
Funding
Takeda.
Disclosure
H. Shoji: Financial Interests, Personal, Advisory Board: Ono Pharmaceutical Co., Ltd., Zymeworks Inc.; Financial Interests, Institutional, Local PI: Ono Pharmaceutical Co., Ltd., MSD, Astellas, Amgen, Daiichi Sankyo; Financial Interests, Institutional, Funding: Ono Pharmaceutical Co., Ltd., Takeda Pharmaceuticals. H. Hirano: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical, Ono Pharmaceutical, Teijin Pharma, Novartis; Financial Interests, Personal, Writing Engagement: Financial Interests, Institutional, Research Grant: Chugai Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Ono Pharmaceutical, Janssen Pharmaceutical, Merck Biopharma, Bristol Myers Squibb, Pfizer, Eisai, Amgen, Astellas, Seagen, MSD, Incyte, BeiGene, Novartis. K. Yamaguchi: Financial Interests, Personal, Invited Speaker: Taiho Pharm; Financial Interests, Personal, Advisory Board: Daiichi Sankyo, Bristol Myers Squibb, Ono Pharm, Eli Lilly Japan; Financial Interests, Institutional, Funding: Taiho. K. Kato: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical, Bristol Myers Squibb, Merck and Co; Financial Interests, Personal, Advisory Board: Ono Pharmaceutical, Bristol Myers Squibb, Merck and Co, Bayer, AstraZeneca, BeiGene, Taiho, Merck Biopharma, Amgen, Novartis, Daiichi Sankyo; Financial Interests, Institutional, Coordinating PI: Ono Pharmaceuticals, Merck & Co; Financial Interests, Institutional, Local PI: Bayer, AstraZeneca, BeiGene, Chugai, Taiho, Oncolys Biopharma, Janssen Pharmaceutical. N. Boku: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Eli Lilly, Ono Pharmaceutical, Taiho, Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Takeda Pharmaceutical, Ono Pharmaceutical. All other authors have declared no conflicts of interest.
Resources from the same session
1508TiP - The 1920-EORTC-BIORADON study: Molecular characterization of non-small cell lung cancer (NSCLC) and indoor radon exposure in Europe
Presenter: Laura Mezquita
Session: Poster session 21
1509TiP - The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor
Presenter: Laura Mezquita
Session: Poster session 21
1510TiP - Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208)
Presenter: Antonio Vitale
Session: Poster session 21
1515P - Maintenance rucaparib after first-line platinum-based chemotherapy in advanced esophagogastric (OG) adenocarcinoma: Interim results from the PLATFORM trial
Presenter: Anderley Gordon
Session: Poster session 21
1518P - Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study
Presenter: Keun-Wook Lee
Session: Poster session 21
1520P - Perioperative treatment in resectable gastric cancer with spartalizumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): The GASPAR phase II trial
Presenter: Melanie Dos Santos
Session: Poster session 21